SEC Form 4 · accession 0001213900-18-002971

REGENERX BIOPHARMACEUTICALS INC · RGRX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Sinaf S.A.

10% Owner

Period of report

Feb 3, 2014

Accepted (ET)

Mar 14, 2018 · 4:30 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000707511

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Feb 3, 2014	J	64,575	$0.00	D	11,584,795	D
Common Stock^F2	Mar 13, 2018	S	11,584,795	$0.23	D	0	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Convertible Promissory Note (right to buy)^F3	$0.06	Mar 13, 2018	S	—	D	Sep 12, 2013	—	Common Stock	—	0	D

Explanation of responses

F1Represents shares escheated to the State of Delaware by the transfer agent. The reporting person did not receive notice of the escheatment and became aware that such shares were escheated during an internal review in 2017. The reporting person has submitted a claim for the payment of the market value of such shares.
F2Represents shares sold by the reporting person and purchased by Essetifin S.p.A., an Italian corporation ("Essetifin"), pursuant to a purchase agreement by and between Essetifin and the reporting person (the "Purchase Agreement").
F3Represents a $150,000 convertible promissory note (the "Note") sold by the reporting person and purchased by Essetifin for an aggregate of $183,780.82, pursuant to the Purchase Agreement. The reporting person purchased the Note on September 12, 2013, from the issuer in a private placement. The Note and any accrued interest thereon are convertible at the option of the holder at any time prior to repayment of the Note into common stock at a conversion price of $0.06 per share. The Note is payable upon the written demand of the holder thereof at any time after September 10, 2018 (the "Maturity Date"). Interest accrues on the unpaid principal amount at a rate equal to 5% per annum, but it is not due and payable until the written demand of the holder for payment on or after the Maturity Date. The current outstanding principal amount, if converted into common stock, would result in the issuance of 2,500,000 shares. The number of shares of common stock to be issued upon conversion will be fixed on the conversion date.